|
Çѱ¹ÇÁ¶óÀÓÁ¦¾à |
Á¦¾à°³¹ßºÎ PVÆÀ ½ÅÀÔ ¹× °æ·ÂÁ÷ ä¿ë
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
03.26 |
|
|
PRA Health Sciences |
[PRA Health Sciences] CRA I, II, III, Drug Safety Associ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.28 |
|
|
(ÁÖ)ÈÞÁ© |
[PVÆÀ] PV °æ·Â
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.10 |
|
|
(ÁÖ)È޿½º |
Huons±×·ì ÀÓ»ó±âȹ½Ç ÀǾàÇ°¾ÈÀü°ü¸® °æ·ÂÁ÷ ä¿ë
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
06.21 |
|
|
(ÁÖ)¹ÙÀ̳ؽº |
ÀÎõ(¼Ûµµ) PV(ÄɹÌÄ®ÆÄÆ®) °æ·Â»ç¿ø ¸ðÁý
ÀÎõ ¿¬¼ö±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
03.29 |
|
|
(ÁÖ)À¯¿µÁ¦¾à |
[°æ·Â] PVÆÀ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
04.25 |
|
|
ÈÞÁ©(ÁÖ) |
[ÀÇÇÐPVÆÀ] MA/MSL ½ÅÀÔ/°æ·Â
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.18 |
|
|
Çö´ë¾àÇ°ÁÖ½Äȸ»ç |
[Çö´ë¾àÇ°] Medical Writer ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
07.20 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK global PS] ERºÎ¼ ÆÀÀå/ ERA °æ·Â/ PL/ A.PL ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.01 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
PV Contract ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.10 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
04.22 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
04.27 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
04.27 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.08 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.12 |
|